Research Paper Volume 14, Issue 15 pp 6316—6337
SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer
Figure 10. Correlation analysis of SAAL1 expression and TME-relevant signatures and immune checkpoint blockade therapy in BLCA. (A) Correlation analysis of SAAL1 expression and TME-relevant signatures. (B) Correlation between high and low SAAL1 expression and therapeutic response to PD-L1 blockade immunotherapy in BLCA patients. (C) SAAL1 expression-based Kaplan-Meier OS curves for BLCA patients who had received anti-PD-L1 immunotherapy. *P<0.05; **P<0.01; ***P<0.001; ns, not significant. Hexp, high SAAL1 expression; Lexp, low SAAL1 expression. Response: CR, complete response; PR, partial response. No response: PD, progressive disease; SD, stable disease.